Emcure Pharmaceuticals Limited

EMCURE

INE168P01015

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 06/02/2026			5-day change	1st Jan Change
1,515.70 ^INR	+2.25%		+3.55%	+11.08%

05/02	Jefferies Adjusts Emcure Pharmaceuticals' Price Target to INR1,780 From INR1,740, Keeps at Buy	MT
04/02	Emcure Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 04, 2026

Emcure Pharmaceuticals Dec-quarter Consol Net Profit 2.31 Billion Rupees

Published on 02/04/2026 at 02:38 pm IST

Reuters

Latest news about Emcure Pharmaceuticals Limited

05/02	Jefferies Adjusts Emcure Pharmaceuticals' Price Target to INR1,780 From INR1,740, Keeps at Buy	MT
04/02	Emcure Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 04, 2026
04/02	Emcure Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
04/02	Emcure Pharmaceuticals Dec-quarter Consol Net Profit 2.31 Billion Rupees	RE
04/02	Diary-India economic, corporate events on February 4	RE
31/01	Delhivery Limited Announces Board Changes	CI
29/01	Emcure Pharmaceuticals Witnesses a Growth Spurt
20/01	Sun Pharma Announces Sana Shaikh Takes Charge as Head of Marketing	CI
09/01	37,959,271 Equity Shares of Emcure Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 9-JAN-2026.	CI
24/12	India equity benchmarks set for muted start amid foreign outflows, thin trading volumes	RE
24/12	Lilly, Novo lock horns in India's obesity drug race	RE
23/12	Emcure Pharmaceuticals says Gujarat facility receives 'No Action Indicated' from US FDA	RE
22/12	Emcure Pharmaceuticals Launches Weight Management Drug Poviztra in India	MT
22/12	Emcure Pharmaceuticals launches Poviztra semaglutide injection in India	RE
22/12	Emcure Pharmaceuticals Limited Expands Weight Management Therapy Access with Launch of Poviztra	CI
15/12	Emcure Pharmaceuticals Ltd Appoints Brijendra Singh as Executive Vice-President	CI
27/11	Emcure Pharmaceuticals says GST department conducts search at Emcure offices	RE
21/11	Emcure Pharmaceuticals Limited Announces Resignation of Chetan Sharma as Company Secretary and Compliance Officer, Effective November 24, 2025	CI
12/11	Jefferies Adjusts Emcure Pharmaceuticals' Price Target to INR1,630 From INR1,610, Keeps at Buy	MT
11/11	Emcure Pharmaceuticals Limited, Q2 2026 Earnings Call, Nov 11, 2025
11/11	Emcure Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
10/11	Emcure Pharma, Novo Nordisk Partner to Launch Semaglutide Brand Poviztra in India	MT
10/11	Novo Nordisk Launches New Weight Loss Drug in India	FW
10/11	Novo Nordisk, Emcure to launch weight-loss drug under new brand in India	RE
10/11	Novo Nordisk to sell weight loss drug Poviztra in India	RE

Chart Emcure Pharmaceuticals Limited

Duration

Period

EMCURE: Dynamic Chart

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.

Employees

6,731

Sector

Pharmaceuticals

Calendar

21/05 - Q4 2026 Earnings Release (Projected)

More about the company